AML1/ETO t(8;21) Quantitative, Real-Time PCR

The AML1/ETO t(8;21) Quantitative, Real-Time PCR test contains 1 test with 1 biomarker.

To detect AML1-ETO t (8;21) fusion transcript that is common in acute myeloid leukemia (AML) M2 subtype. Besides initial diagnosis and prognosis evaluation, this assay is intended to monitor the clinical course and effectiveness of therapy of Minimal Residual Disease (MRD). It may be valuable to monitor the disease trend in the same patient and predict the approaching relapse

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

Also known as: AML1ETO t821 Quantitative RealTime PCR

Aml1-Eto T(8.21)